IBM pushes back on negative Watson Health stories

IBM Watson Health (NYSE:IBM) is pushing back against reports that its artificial intelligence powered products deliver less than promised, claiming that the reports are unfair and ignore its capabilities. A number of news outlets, including The Wall Street Journal and STAT News, have recently published criticisms of IBM’s Watson Health offerings, claiming that its capabilities fall short of the company’s large promises. “Unfortunately, some media reports, including an August 11th story published in The Wall Street Journal, distort and ignore facts when suggesting IBM has not made ‘enough’ progress on bringing the benefits of AI to healthcare. I feel it is imperative to set the record straight,” IBM Watson Health cognitive solutions senior VP Dr. John Kelly III wrote in a blog post for the company. In a report from STAT News released last month, investigators obtained internal documents from IBM Watson Health that the outlet said show that the company’s Watson for Oncology product often returns “multiple examples of unsafe and incorrect treatment recommendations.” “We have always believed that the role of technology is to assist a doctor in delivering better care and patient outcomes. Therefore, the first question we asked ourselves was, ‘can Watson help oncologists make better decisions for their patients?’ Repeatedly, the answer has proven to be a resounding ‘yes,’ as demonstrated in both peer-reviewed researc...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Software / IT IBM Watson Health Source Type: news